Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept effects on synovial biomarkers in rheumatoid arthritis
NL-OMON34549Phase 4Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2010
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of abatacept in rheumatoid arthritis (RA), sponsored by Amsterdam University Medical Center. Primary endpoint: Change in synovial inflammation. Planned start Sep 2010; status: not yet recruiting.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON34549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34549.